Summary
218.37 -0.20(-0.09%)05/20/2024
Resmed Inc. (RMD)
Resmed Inc. (RMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.35 | 0.89 | 15.14 | 15.83 | 43.87 | -7.10 | 97.96 | 37,407.35 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 216.18 | |
| Open | 217.20 | |
| High | 217.24 | |
| Low | 215.71 | |
| Volume | 586,017 | |
| Change | -0.76 | |
| Change % | -0.35 | |
| Avg Volume (20 Days) | 1,380,956 | |
| Volume/Avg Volume (20 Days) Ratio | 0.42 | |
| 52 Week Range | 132.26 - 237.26 | |
| Price vs 52 Week High | -8.88% | |
| Price vs 52 Week Low | 63.45% | |
| Range | -0.47 | |
| Gap Up/Down | -1.29 | |
Fundamentals | ||
| Market Capitalization (Mln) | 32,134 | |
| EBIDTA | 1,441,419,008 | |
| PE Ratio | 32.8954 | |
| PEG Ratio | 1.7534 | |
| WallStreet Target Price | 212.34 | |
| Book Value | 31.5200 | |
| Earnings Per Share | 6.5000 | |
| EPS Estimate Current Quarter | 1.9100 | |
| EPS Estimate Next Quarter | 1.9600 | |
| EPS Estimate Current Year | 7.7300 | |
| EPS Estimate Next Year | 8.6300 | |
| Diluted EPS (TTM) | 6.5000 | |
| Revenues | ||
| Profit Marging | 0.2091 | |
| Operating Marging (TTM) | 0.3129 | |
| Return on asset (TTM) | 0.1191 | |
| Return on equity (TTM) | 0.2239 | |
| Revenue TTM | 4,584,159,232 | |
| Revenue per share TTM | 31.1750 | |
| Quarterly Revenue Growth (YOY) | 0.0720 | |
| Quarterly Earnings Growth (YOY) | 0.2910 | |
| Gross Profit (TTM) | 2,386,058,000 | |
| Dividends | ||
| Dividend Share | 1.8800 | |
| Dividend Yield | 0.0090 | |
| Valuations | ||
| Trailing PE | 32.8954 | |
| Forward PE | 23.3100 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.0997 | |
| Revenue Enterprise Value | 6.3318 | |
| EBITDA Enterprise Value | 19.9430 | |
| Shares | ||
| Shares Outstanding | 146,907,008 | |
| Shares Float | 145,468,985 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.08 | |
| Insider (%) | 0.82 | |
| Institutions (%) | 59.54 | |
05/20 11:50 EST - zacks.com
Here's Why Investors Should Buy ResMed (RMD) Stock Now
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
Here's Why Investors Should Buy ResMed (RMD) Stock Now
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
05/16 16:35 EST - globenewswire.com
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024 Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below.
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024 Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below.
05/16 13:01 EST - zacks.com
What Makes ResMed (RMD) a New Strong Buy Stock
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes ResMed (RMD) a New Strong Buy Stock
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
05/15 13:46 EST - zacks.com
Here is Why Growth Investors Should Buy ResMed (RMD) Now
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Here is Why Growth Investors Should Buy ResMed (RMD) Now
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
05/15 10:51 EST - zacks.com
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
05/14 07:46 EST - zacks.com
4 Top Stocks to Invest in for Astounding Earnings Growth
Invest in stocks such as BellRing Brands (BRBR), ResMed (RMD), NVIDIA (NVDA) and Transdigm Group (TDG) for solid earnings growth.
4 Top Stocks to Invest in for Astounding Earnings Growth
Invest in stocks such as BellRing Brands (BRBR), ResMed (RMD), NVIDIA (NVDA) and Transdigm Group (TDG) for solid earnings growth.
05/13 09:11 EST - zacks.com
U.S. Consumer Sentiment Plummets in May: 5 Safe Stock Picks
We have narrowed our search to five defensive stocks with strong potential for the rest of 2024. These are: ES, ATO, MKC, TSN, RMD.
U.S. Consumer Sentiment Plummets in May: 5 Safe Stock Picks
We have narrowed our search to five defensive stocks with strong potential for the rest of 2024. These are: ES, ATO, MKC, TSN, RMD.
05/08 12:05 EST - zacks.com
3 GARP Stocks to Scoop up for Maximum Returns
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.
3 GARP Stocks to Scoop up for Maximum Returns
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.
05/03 09:46 EST - zacks.com
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.
04/30 10:56 EST - zacks.com
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
04/29 18:21 EST - zacks.com
Top Stocks to Buy with Rising EPS Estimates After Earnings
These companies saw their stocks spike after impressively beating earnings expectations last week and more upside could be ahead considering EPS estimates for fiscal 2024 have trended higher afterwards.
Top Stocks to Buy with Rising EPS Estimates After Earnings
These companies saw their stocks spike after impressively beating earnings expectations last week and more upside could be ahead considering EPS estimates for fiscal 2024 have trended higher afterwards.
04/29 13:47 EST - zacks.com
Looking for a Growth Stock? 3 Reasons Why ResMed (RMD) is a Solid Choice
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Looking for a Growth Stock? 3 Reasons Why ResMed (RMD) is a Solid Choice
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
04/29 10:46 EST - zacks.com
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
04/26 17:20 EST - investopedia.com
S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep Devices
Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher on Friday.
S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep Devices
Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher on Friday.
04/26 12:08 EST - fool.com
Why ResMed Stock Is Soaring Today
ResMed easily beat Wall Street's earnings estimates for its fiscal Q3. The company's products are enjoying strong demand.
Why ResMed Stock Is Soaring Today
ResMed easily beat Wall Street's earnings estimates for its fiscal Q3. The company's products are enjoying strong demand.
04/26 10:00 EST - investors.com
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
04/26 09:41 EST - zacks.com
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
04/26 08:33 EST - barrons.com
ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.
The medical devices company beat expectations for its fiscal third quarter.
ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.
The medical devices company beat expectations for its fiscal third quarter.
04/25 21:38 EST - seekingalpha.com
ResMed Inc. (RMD) Q3 2024 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q3 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Marquee Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Bailey - Macquarie Anthony Petrone - Mizuho Group Suraj Kalia - Oppenheimer Margaret Kaczor-Andrew - William Blair Gretel Janu - E&P Brett Fishbin - KeyBanc Mike Matson - Needham & Company Lyanne Harrison - Bank of America Steve Wheen - Jarden Saul Hadassin - Barrenjoey Capital Mike Toomey - Jefferies Operator Hello. And welcome to the Q3 Fiscal Year 2024 ResMed Earnings Conference Call.
ResMed Inc. (RMD) Q3 2024 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q3 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Marquee Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Bailey - Macquarie Anthony Petrone - Mizuho Group Suraj Kalia - Oppenheimer Margaret Kaczor-Andrew - William Blair Gretel Janu - E&P Brett Fishbin - KeyBanc Mike Matson - Needham & Company Lyanne Harrison - Bank of America Steve Wheen - Jarden Saul Hadassin - Barrenjoey Capital Mike Toomey - Jefferies Operator Hello. And welcome to the Q3 Fiscal Year 2024 ResMed Earnings Conference Call.
04/25 19:31 EST - zacks.com
Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.